Q1 EPS Estimates for Prime Medicine Lifted by HC Wainwright

Prime Medicine, Inc. (NYSE:PRME - Free Report) - Research analysts at HC Wainwright lifted their Q1 2025 EPS estimates for Prime Medicine in a research report issued to clients and investors on Monday, March 3rd. HC Wainwright analyst A. He now forecasts that the company will post earnings per share of ($0.35) for the quarter, up from their previous estimate of ($0.36). HC Wainwright has a "Buy" rating and a $10.00 price objective on the stock. The consensus estimate for Prime Medicine's current full-year earnings is ($1.68) per share. HC Wainwright also issued estimates for Prime Medicine's Q2 2025 earnings at ($0.35) EPS, Q3 2025 earnings at ($0.29) EPS, Q4 2025 earnings at ($0.30) EPS, FY2025 earnings at ($1.28) EPS, FY2026 earnings at ($1.33) EPS, FY2027 earnings at ($1.33) EPS, FY2028 earnings at ($1.12) EPS and FY2029 earnings at ($0.75) EPS.

Several other analysts also recently commented on PRME. StockNews.com upgraded shares of Prime Medicine to a "sell" rating in a report on Tuesday, February 11th. Citizens Jmp raised shares of Prime Medicine to a "strong-buy" rating in a research report on Tuesday, December 10th. JMP Securities assumed coverage on shares of Prime Medicine in a research note on Tuesday, December 10th. They issued an "outperform" rating and a $10.00 target price for the company. Wedbush reissued an "outperform" rating and issued a $12.00 price target on shares of Prime Medicine in a research note on Friday, February 28th. Finally, Chardan Capital restated a "buy" rating and issued a $15.00 price target on shares of Prime Medicine in a report on Monday, March 3rd. One research analyst has rated the stock with a sell rating, nine have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $13.13.

Remove Ads

Prime Medicine Trading Down 13.3 %

Shares of NYSE:PRME traded down $0.32 during trading on Thursday, hitting $2.08. 1,884,985 shares of the company's stock traded hands, compared to its average volume of 1,072,122. The company has a 50-day moving average price of $2.80 and a 200-day moving average price of $3.35. Prime Medicine has a 52 week low of $2.04 and a 52 week high of $8.35. The company has a market cap of $272.81 million, a price-to-earnings ratio of -1.01 and a beta of 1.85.

Prime Medicine (NYSE:PRME - Get Free Report) last posted its earnings results on Friday, March 7th. The company reported ($1.65) earnings per share (EPS) for the quarter. During the same quarter in the previous year, the business earned ($2.18) earnings per share.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the stock. ProShare Advisors LLC boosted its holdings in shares of Prime Medicine by 24.6% in the 4th quarter. ProShare Advisors LLC now owns 22,186 shares of the company's stock valued at $65,000 after buying an additional 4,375 shares during the last quarter. China Universal Asset Management Co. Ltd. lifted its stake in Prime Medicine by 20.5% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 27,811 shares of the company's stock valued at $81,000 after acquiring an additional 4,725 shares during the last quarter. Levin Capital Strategies L.P. grew its position in shares of Prime Medicine by 7.1% in the 4th quarter. Levin Capital Strategies L.P. now owns 75,000 shares of the company's stock valued at $219,000 after acquiring an additional 5,000 shares during the period. PEAK6 Investments LLC increased its stake in shares of Prime Medicine by 32.4% during the 3rd quarter. PEAK6 Investments LLC now owns 45,013 shares of the company's stock worth $174,000 after purchasing an additional 11,013 shares during the last quarter. Finally, American Century Companies Inc. acquired a new position in shares of Prime Medicine during the 4th quarter worth about $33,000. Institutional investors and hedge funds own 70.37% of the company's stock.

About Prime Medicine

Prime Medicine, Inc, a biotechnology company, delivers genetic therapies to address the spectrum of diseases by deploying gene editing technology. The company offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence.